Clinical

Primary care providers utilize many strategies for prioritizing preventive care during time-constrained clinical encounters, in addition to being prompted by clinical reminders.

Identifying which patients are likely to benefit from care coordination is important. We evaluated the performance of 6 risk-screening instruments in predicting healthcare utilization.

Home blood pressure (BP) monitoring and use of secure webbased tools to manage care collaboratively with pharmacists is a cost-effective way to improve BP control.

States offering pharmacists full immunization privileges have significantly higher vaccination uptake rates for pneumococcal disease and herpes zoster than states with restricted or no authorization.

Coupons and vouchers for name-brand prescription drugs claim to cut costly out-of-pocket expenses, but they actually may be doing very little to control prices.

Between 2005 and 2011, rates of cardiac catheterization laboratory false activation doubled while mean door-to-balloon times for primary PCI declined.

According to several healthcare CIOs giving testimony yesterday in the District of Columbia, hospitals are pressed for both time and money when it comes to implementing the necessary changes to their EHR systems and clinical workflows.

Adrian Wiestner, MD, PhD, Investigator, Laboratory of Lymphoid Malignancies, National Heart Lung and Blood Institute, discusses the patient outcomes that clinical trials have demonstrated regarding the use of targeted kinase inhibitors for the management of chronic lymphocytic leukemia (CLL).

Journal of Oncology Practice (JOP) and The American Journal of Managed Care (AJMC) join efforts to highlight work focusing on issues affecting payers and providers.

Bimal Patel, PharmD, MS, Director, Health Outcomes Research, MedImpact Healthcare Systems, Inc., discusses MedImpact's work to identify, analyze, and evaluate generic medications that have become significantly expensive, and effective strategies for managing these costs.

Korean drug maker Celltrion Healthcare recently presented new findings from a 2-part study at the Annual European Congress of Rheumatology 2019 meeting about subcutaneous biosimilar CT-P13 (Inflectra, Remsima).